Clinical response to supervised treatment of Colombian patients with cutaneous
leishmaniasis was evaluated in a randomized controlled trial comparing 10 days versus 20 …

Sixty-six Guatemalan men with parasitologically confirmed cutaneous leishmaniasis, due
most commonly to Leishmania braziliensis, were randomly assigned to receive one of three …

We retrospectively analyzed a series of 151 cases of cutaneous leishmaniasis treated
between 1967 and 1982. One-hundred-and-thirty-nine (92%) patients presented with active …

Of 400 patients 6 to 17 years old in Algeria with L. major infection 97 were treated with
meglumine antimonate (60 mg/kg/day intramuscularly for 15 days), 80 with metronidazole …

We conducted a quasi-experimental study to compare the response to meglumine
antimoniate in patients with localized cutaneous leishmaniasis from two endemic areas of …

We evaluated the effectiveness and safety of intralesional meglumine antimoniate (MA) in
24 not submitted to previous treatment patients with cutaneous leishmaniasis (CL) and with …

Ninety-two patients in Colombia with cutaneous leishmaniasis were randomly assigned to
groups to be treated with meglumine antimonate (infected control subjects; 10 mg of …

Some studies showed that children have a lower response to systemic use of pentavalent
antimoniate than adults. We aimed to evaluate the response rate to Glucantime therapy in …

INTRODUCTION: Intralesional treatment for cutaneous leishmaniasis has been applied for
over 30 years at the Oswaldo Cruz Foundation, Rio de Janeiro, with good therapeutic results …

Pentamidine was compared with meglumine antimoniate (Glucantime) for 80 patients with
cutaneous leishmaniasis due to Leishmania braziliensis in Peru. Of the 40 patients …